共 49 条
- [41] Amcenestrant in combination with CDK4/6 inhibitor palbociclib demonstrates synergistic anti-tumor activity in ER plus endocrine-resistant breast cancer xenograft modelsCANCER RESEARCH, 2022, 82 (04)Shomali, MaysounGuo, ZhuyanCheng, JaneSullivan, AmyEl-Ahmad, YoussefSun, FangxianSidhu, SukhvinderLee, Joon SangCai, HuiPollard, JackDebussche, LaurentSoria, ChrisBouaboula, Monsif
- [42] Composite Copy Number Variation in CDK4, CDKN2A and RB1 Predisposes Mantle Cell Lymphoma to Expansion of PD1+Tumor Cells and Resistance to CDK4/6 Inhibitor Therapy as Revealed by Integrative Longitudinal scRNA-seqBLOOD, 2019, 134Di Liberto, MaurizioHu, YangHuang, XiangaoLee, Christina Y.Wang, KevinBartlett, Nancy L.Ridling, LeannBlum, Kristie A.Maddocks, Kami J.Park, Steven I.Ruan, JiaEng, KennethGalluzzi, LorenzoLeonard, John P.Martin, PeterElemento, OlivierChen-Kiang, Selina
- [43] Combination of complete estrogen receptor antagonist, OP-1250, and CDK4/6 inhibitors enhances tumor suppression and inhibition of cell cycle-related gene expressionCANCER RESEARCH, 2023, 83 (05)Parisian, Alison D.Palanisamy, Gopinath S.Ortega, FabianSapugay, Judevin L.Bodell, William J.Kulp, DavidKushner, PeterHarmon, Cyrus
- [44] Integrative Whole Transcriptome and Exome Sequencing Reveals Reprogramming Of Mantle Cell Lymphoma In Prolonged Early G1 Arrest For Clinical Response To Selective Inhibition Of CDK4 In Combination TherapyBLOOD, 2013, 122 (21)Chiron, DavidMartin, PeterDi Liberto, MaurizioHuang, XiangaoVijay, PriyankaBlecua, PedroEly, Scott A.Elemento, OlivierMason, Christopher E.Leonard, John P.Chen-Kiang, Selina
- [45] Combination of CDK4/6 Inhibitor Palbociclib and PI3K Inhibitor Idelalisib Synergistically Induces an Anti-Tumor Effect in B-Cell Lymphoma and Overcomes Ibrutinib ResistanceBLOOD, 2023, 142Hu, DingyaoCao, JiaowuWang, DedaoWu, JiajinMi, LanPing, LingyanDing, NingSong, YuqinZhu, Jun
- [46] Cooperative Repression of IRF4 and Induction of IRF7 By CDK4/6 Inhibition Sensitizes Mantle Cell Lymphoma Cells to IMiD-Mediated Apoptosis Independent of p16 Deletion or c-Myc OverexpressionBLOOD, 2018, 132Humos, Basel A.Di Liberto, MaurizioHuang, XiangaoElemento, OlivierChen-Kiang, Selina
- [47] Dual Inhibition of PKC Delta By Carfilzomib (CFZ) and Ibrutinib Results in Synergistic Activity in Rituximab-Chemotherapy Sensitive and Resistant Lymphoma Pre-Clinical Models and in Primary Tumor Cells Isolated from B-Cell Lymphoma PatientsBLOOD, 2015, 126 (23)Zhang, QunlingGu, Juan J.Guo, YeKlos, JacobMavis, CoryCzuczman, Myron S.Hernandez-Ilizaliturri, Francisco J.
- [48] CDK2 inhibition with BLU-222 in combination with ribociclib demonstrates robust antitumor activity in pre-clinical models of CDK4/6 inhibitor-naive and -resistant HR+/HER2-breast cancerCANCER RESEARCH, 2023, 83 (05)Brown, VictoriaHouse, NealiaRamsden, PhilHo, KarenWu, Hsin-JungWilker, ErikGuo, JianChen, MaxineWilson, DouglasBifulco, NeilWenglowsky, SteveChoi, Yoon JongFaia, Kerrie
- [49] Palbociclib (PD-0332991), a Potent Selective CDK4/6 Inhibitor, Overcomes Therapy-Resistant and Sensitizes Diffuse Large B-Cell Lymphoma Pre-Clinical Models to Chemo-ReagentsBLOOD, 2015, 126 (23)Gu, Juan J.Zhang, QunlingMavis, CoryCzuczman, Myron S.Hernandez-Ilizaliturri, Francisco J.